

Press Release

Heerlen (NL), 18 March 2015

Royal DSM
media.contacts@dsm.com
www.dsm.com

05E

DSM Managing Board re-appointments

Royal DSM, the global Life Sciences and Materials Sciences company, today announces the proposed re-appointment of Stephan B. Tanda as member of the DSM Managing Board at the upcoming Annual General Meeting of Shareholders (AGM) on 30 April 2015. DSM also announces the departure of DSM Managing Board member Stefan Doboczky per 1 June 2015.

The transformation of the DSM pharmaceutical activities was completed in 2014, and DSM now holds participations in two joint ventures. As a result, it has been agreed between DSM and Stefan Doboczky that his term as a Managing Board member will not be renewed at the upcoming AGM. Stefan will leave DSM per 1 June and has accepted employment outside of DSM.

Stefan Doboczky has worked in DSM's Pharma businesses for 17 years and has, as a Managing Board member, successfully led the design and execution of the Pharma strategy, resulting in the creation of DSM Sinochem Pharmaceuticals (DSP, Antibiotics JV with Sinochem) and DPx (Pharma JV with JLL/Patheon).

The responsibilities of Stefan Doboczky will be redistributed among the current Managing Board members.

Feike Sijbesma, CEO and Chairman of the DSM Managing Board, commented: *"During the years that Stefan worked for DSM in Pharma and as Regional President in Asia, he spearheaded many strategic growth initiatives that helped transform our business. DSM is very grateful for the contribution he has made over many years and, also on behalf of my colleagues, I wish him every success in the next step in his career."*

DSM - Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

Or find us on:    

For more information:

DSM Corporate Communications
Herman Betten
tel. +31 (0) 45 5782017
e-mail media.contacts@dsm.com

DSM Investor Relations
Dave Huizing
tel. +31 (0) 45 5782864
e-mail investor.relations@dsm.com

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.